Marlborough diagnostic company Immunovia, Inc. announced on Monday it has acquired a global license from the South Korean company JW BioScience’s intellectual property portfolio, granting Immunovia global commercial rights for two biomarkers.
The license agreement strengthens patent protection and secures intellectual property rights for pancreatic cancer biomarkers discovered by Immonovia and used for its IMMray PanCan-d detection test.
Details of the deal size were not disclosed.
“By entering into this agreement, Immunovia and JW BioScience will also evaluate possibilities for commercial collaboration to enable early detection of pancreatic cancer in the Korean market,” Patrik Dahlen, CEO of Immunovia, said in a statement.Â
